You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advanced Prodrug Treatment for CML

    SBC: Inhibikase Therapeutics, Inc.            Topic: 399

    Inhibikase Therapeutics is a clinical stagebio pharmaceutical company that has developed a novel prodrug formulation for the popular anticancer agent GleevecGleevectreatment is commonly accompanied by significantburdensome gastrointestinal side effectsfatigue and myalgias that erode therapy success due to poor patient complianceInhibikaseandapos s prodrug of GleevecIkTProProcompletely blunts these ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NIAAA

    Abstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a protein drug for pancreatic cancer treatment

    SBC: ProDa BioTech L.L.C.            Topic: NCI

    Abstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Data Intelligence & Advanced Analytics to Reduce Drug Diversion across the Care Delivery Cycle and Drug Supply Chain in Health Systems

    SBC: Invistics Corporation            Topic: NIDA

    This SBIR project will research mechanisms to detect when Health Care WorkersHCWsin hospitals steal ordivertlegal drugs either to abuse themselves or to illegally sell to othersWe focus on HCWs in hospitals because of the alarming rates of substance abuse and diversion in hospitalswith multiple studies finding roughlyof our nation s nursesanesthesiologistsand pharmacists are currently diverting dr ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Microhook nerve tape: A nerve repair coaptation aid

    SBC: Axion Biosystems, Inc.            Topic: 101

    Project Summary We will finalize development of a microhook based device for quick and consistently effective repair of nerve injuriesThismicrohook nerve tapeconsists of an array of microscale hooksdistributed across a fineflexible meshwork and embedded in a biologic backingThis device will be used during nerve repair surgeries in place of microsutures to wrap around and bind the approximated ends ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic

    SBC: EXPRESSION THERAPEUTICS, LLC            Topic: NHLBI

    PROJECT SUMMARY ABSTRACT The long term objective of current project is to commercialize a novel coagulation factor product manufactured using a novel production cell linedesignated ET i BHK M with a primary indication of treatment of anti drug antibodies that develop following the treatment of congenital hemophilia A with factor VIIIfVIIIreplacement productsExpression Therapeutics has developed mu ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Hemonauts- Interactive Digital Media for Increased STEM Learning Among Chronically Ill Children and Their Support Networks

    SBC: Thrust Interactive, Inc.            Topic: 500

    Abstract This proposal seeks to create the Hemonauts suite of interactive digital mediaIDMto serve chronically illfrequently hospitalized students in grades five through eight and their support networks toiIncrease STEM content knowledge through gameplayiiIncrease knowledge of and intent to persist in STEM careersandiiiIncrease disease literacy to improve patient self advocacytreatment compliancea ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government